Erectile Dysfunction Drugs Market Size Worth USD 5.54 Billion in 2032 | Emergen Research

The global Erectile Dysfunction (ED) drugs market size was USD 2.46 Billion in 2022 and is expected to register a revenue CAGR of 8.4% during the forecast period. The global market for erectile dysfunction (ED) drugs is set to experience significant growth, driven by various factors including the rising prevalence of ED disorders, lifestyle changes, and advancements in product approvals and launches. According to recent market analysis, the market is expected to see substantial revenue expansion over the forecast period.

Key Drivers:

1. Rising Prevalence of Erectile Dysfunction Disorders: Erectile dysfunction, a highly prevalent condition affecting millions of men worldwide, continues to be a significant health concern. Factors such as sedentary lifestyles and increasing psychological disorders contribute to its prevalence.

2. Growing Adoption of Sedentary Lifestyle & Low Drug Costs: Lifestyle factors, including sedentary behaviors, contribute to the increased incidence of ED. Furthermore, the availability of ED drugs at relatively low costs facilitates greater accessibility for patients.

3. Increasing Product Approval and Launches: Recent approvals, such as the over-the-counter sale of MED3000 (Eroxon) by the US Food and Drug Administration (FDA), reflect a growing trend in product approvals, offering patients more treatment options.

Request a Sample Report with Table of Contents and Figures to click Here: @ https://www.emergenresearch.com/request-sample/2824

Market Restraints:

1. Patient Reluctance and Counterfeit Drugs: Despite the availability of treatments, patient reluctance to seek treatment and the prevalence of counterfeit drugs pose challenges to market growth.

2. Adverse Effects and Patent Expiration: Concerns about adverse effects of ED drugs and the expiration of patents on blockbuster drugs may hinder market expansion.

3. Healthcare Infrastructure and Manufacturing Issues: Challenges related to healthcare infrastructure and manufacturing issues, exemplified by recalls like that of Sun Pharmaceutical Industries Ltd.'s generic drug Tadalafil, may impact market growth.

Segment Insights:

1. Product Dynamics: Segmentation of the market into various products such as Stendra/Spedra showcases the diversity of available treatments and their respective market shares.

2. Mode of Administration: The market segmentation by mode of administration, including oral doses and injections, highlights the preferences and growth potentials of different administration methods.
3.
4. Distribution Channels: Distribution channels like retail pharmacies and hospital pharmacies play crucial roles in making ED drugs accessible to patients, influencing market dynamics.

Requesting A Customised Report @https://www.emergenresearch.com/request-for-customization/2824

Erectile Dysfunction Drugs Top Companies and Competitive Landscape

The global erectile dysfunction drugs market is fragmented, with several medium and large-sized players accounting for majority of market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing erectile dysfunction drugs.

• Pfizer Inc.
• Ferring B.V.
• Bayer AG
• Coloplast Corp
• Boston Scientific Corporation
• SK chemicals.
• Teva Pharmaceutical Industries Ltd.
• Meda Pharmaceuticals
• GSK plc.
• Sanofi
• Futura Medical
• CURE Pharmaceutical
• Initiator Pharma
• Aquestive Therapeutics, Inc.
• Astellas Pharma Inc.
• Benuvia, Inc.
• Lupin.
• Eli Lilly and Company.
• Sun Pharmaceutical Industries Ltd.
• Arovella Therapeutics

Erectile Dysfunction Drugs Latest Industry News

• In May 2022, Aspargo Laboratories, Inc., a privately held specialty pharmaceutical company focused on commercializing innovative formulations of leading medications, has announced the acquisition of the prescription brand BANDOL (sildenafil oral suspension) from Laboratorios Rubio S.A., based in Barcelona, Spain. Aspargo signed a distribution arrangement with Rubio to continue marketing and promoting BANDOL in Spain, as well as a license and supply agreement with Farmalider, S.A. to supply BANDOL to the Spanish market.

• In September 2021, iX Biopharma Ltd, a specialty pharmaceutical company, has licensed, supplied, and distributed Wafesil, a sublingual sildenafil wafer for the treatment of male erectile dysfunction, in China through its wholly owned subsidiary China Resources Pharmaceutical Commercial Group International Trading Co., Ltd.

To Read More About The Report, Visit @https://www.emergenresearch.com/industry-report/erectile-dysfunction-drugs-market

Erectile Dysfunction Drugs Market Segment Analysis

For the purpose of this report, Emergen research has segmented the global erectile dysfunction drugs market on the basis of product, indication, age group, mode of administration, distribution channel, and region:

• Product Outlook (Revenue, USD Billion; 2019-2032)
o Helleva
o Levitra/Staxyn
o Medicated Urethral System for edifice (MUSE)
o Mvix
o Stendra/Spedra
o Zydena

• Age Group Outlook (Revenue, USD Billion; 2019-2032)
o Less than 40 years
o 40-60 years
o More than 60 years

• Mode of Administration Outlook (Revenue, USD Billion; 2019-2032)
o Topical Dose
o Oral Dose
o Injection
o Others

• Distribution Channel Outlook (Revenue, USD Billion; 2019-2032)
o Online Sales
o Hospital Pharmacies
o Retail Pharmacies
o Others

• Regional Outlook (Revenue, USD Billion; 2019-2032)
o North America
1. U.S.
2. Canada
3. Mexico
o Europe
1. Germany
2. France
3. U.K.
4. Italy
5. Spain
6. Benelux
7. Rest of Europe
o Asia Pacific
1. China
2. India
3. Japan
4. South Korea
5. Rest of APAC
o Latin America
1. Brazil
2. Rest of LATAM
o Middle East & Africa
1. Saudi Arabia
2. UAE
3. South Africa
4. Turkey
5. Rest of MEA

To Purchase Now, Click Here @https://www.emergenresearch.com/select-license/2824

Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Visit for More Insights: https://www.emergenresearch.com/insights

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.

This release was published on openPR.